We use strictly necessary cookies to make our site work. We would also like to set optional cookies (analytical, functional and YouTube) to enhance and improve our service. You can opt-out of these cookies. By clicking “Accept All Cookies” you can agree to the use of all cookies.

Cookies Statement and Privacy Statement

Best-value biological medicines

The Medicines Management Programme has identified best-value biological (BVB) medicines for TNF-α inhibitors under the High Tech Arrangement.

The MMP recommends the following BVB medicines for adalimumab and etanercept:

  •  Adalimumab:

              o   Citrate-containing: Idacio, Imraldi

              o   Citrate-free: Amgevita, Hulio

  •  Etanercept: Benepali

Clinicians should give due consideration to the prescription of these agents when prescribing a TNF-α inhibitor. Implementation of the BVB medicines will lead to significant savings for the health service, in the order of millions of euros.

Resources to support prescribing of the BVB medicines are located in the Related Files section below:

  • Questions and Answers for Healthcare Professionals.
  • MMP Product Information Sheets for Amgevita, Benepali, Hulio, Idacio and Imraldi.
  • Contact information for MMP support.
  • Contact information for patient support services for Amgevita, Benepali, Hulio, Idacio and Imraldi.
  • Templates for switching letters for Amgevita, Benepali, Hulio, Idacio and Imraldi.

From 1 February 2020, it is HSE policy that all adult patients who are commencing treatment with adalimumab or etanercept should be prescribed a best-value biological (BVB) medicine. Further information in relation to this can be found here.

The MMP wrote a letter to prescribers updating them on the BVB medicine initiative in September 2020.

Clinical Strategy and Programmes Division